Objective: Description of some side effects of Emla 5% and factors related to pain levels in parturients during spinal anesthesia and epidural anesthesia in cesarean section patients.
Object and methods: Clinical interventional, descriptive, cross-sectional, controlled study. 120 women were randomly divided into 3 equal groups: group L (using only Lidocaine), group E (using only Emla 5%) and group E/L (using a combination of Emla 5% and Lidocaine 1%). Side effects occurring in the parturients were monitored and recorded, some factors related to the degree of pain experienced by parturients during spinal anesthesia and epidural anesthesia.
Results: Using Emla 5% for pain reduction at spinal and epidural anesthesia sites in cesarean section patients showed no local or systemic adverse effects in both the Emla 5% monotherapy group and the Emla 5% combined with Lidocaine group. Neonatal Apgar scores in all three groups ranged from 8-10 points, with equivalent outcomes across all three study groups (p > 0,05). Pain level distributions were comparable between urban and rural maternal groups, and between primiparous and multiparous cesarean delivery groups.
Conclusion: The use of Emla 5% cream reduces pain at spinal and epidural anesthesia injection sites for cesarean section patients, demonstrating safety for both mothers and neonates, with no documented local or systemic adverse effects observed in groups receiving Emla alone or Emla combined with Lidocaine. Geographic factors and history of cesarean section are independent factors that do not influence the level of pain experienced by parturients during spinal anesthesia and epidural anesthesia.